Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. Cala Trio is indicated to aid in the transient relief of hand tremors in the treated hand following stimulation in adults with essential tremor. Please refer to the Safety Information [https://calatrio.com/#SafetyInformation] for a complete listing of warnings and cautions. Caution: Federal law restricts this device to sale by or on the order of a physician. _______________ 1 Isaacson, S. H., Peckham, E., Tse, W., Waln, O., Way, C., Petrossian, M. T., … Pahwa, R. (2020). Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor and Other Hyperkinetic Movements, 10, 29. DOI: http://doi.org/10.5334/tohm.59 2 PND44 Patient Characteristics and Comorbidities in Patients with Essential Tremor: A Retrospective Observational Study in a United States Commercially Insured and Medicare Advantage Population. Dai, D. et al. Value in Health, Volume 24, S167